Five decades of Fontan palliation: What have we learned? What should we expect?

被引:3
|
作者
Hassan, Adil [1 ]
Chegondi, Madhuradhar [2 ]
Porayette, Prashob [3 ]
机构
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Stead Family Childrens Hosp, Div Pediat Crit Care Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Stead Family Childrens Hosp, Div Pediat Cardiol, Iowa City, IA 52242 USA
关键词
Single-ventricle physiology; Fontan; congenital heart disease; neurodevelopmental outcomes; adult congenital heart disease; arrhythmias; cyanosis; heart failure; cardiac transplantation; Fontan-associated liver disease; CONGENITAL HEART-DISEASE; PROTEIN-LOSING ENTEROPATHY; SINGLE VENTRICLE; CONSENSUS DOCUMENT; CLINICAL-OUTCOMES; AMERICAN-SOCIETY; VENOUS-PRESSURE; ARTERIAL DUCT; LONG-TERM; ADULTS;
D O I
10.1177/03000605231209156
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Fontan procedure is the final palliative surgery in a series of staged surgeries to reroute the systemic venous blood flow directly to the lungs, with the ventricle(s) pumping oxygenated blood to the body. Advances in medical and surgical techniques have improved patients' overall survival after the Fontan procedure. However, Fontan-associated chronic comorbidities are common. In addition to chronic cardiac dysfunction and arrhythmias, complications involving other organs such as the liver, lungs, intestine, lymphatic system, brain, and blood frequently occur. This narrative review focuses on the immediate and late consequences in children, pregnant women, and other adults with Fontan circulation. In addition, we describe the technical advancements that might change the way single-ventricle patients are managed in future.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] What we have learned
    Macwhinney, Brian
    JOURNAL OF CHILD LANGUAGE, 2014, 41 : 124 - 131
  • [2] Arthroereisis What Have We Learned?
    Ortiz, Cristian A.
    Wagner, Emilio A.
    Wagner, Pablo A.
    FOOT AND ANKLE CLINICS, 2018, 23 (03) : 415 - +
  • [3] Tight glycemic control: what do we really know, and what should we expect?
    Nasraway, Stanley A., Jr.
    Rattan, Rishi
    CRITICAL CARE, 2010, 14 (05):
  • [4] Acute megakaryocytic leukemia: What have we learned
    Hahn, Andrew W.
    Li, Bojia
    Prouet, Philippe
    Giri, Smith
    Pathak, Ranjan
    Martin, Mike G.
    BLOOD REVIEWS, 2016, 30 (01) : 49 - 53
  • [5] Coronary stent thrombosis: what have we learned?
    Collet, Carlos
    Sotomi, Yohei
    Cavalcante, Rafael
    Suwannasom, Pannipa
    Tenekecioglu, Erhan
    Onuma, Yoshinobu
    Serruys, Patrick W.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : 1398 - 1405
  • [6] Levosimendan: What Have We Learned So Far?
    Villa, Giulia
    Tavazzi, Guido
    Guarracino, Fabio
    Sangalli, Fabio
    CURRENT ANESTHESIOLOGY REPORTS, 2019, 9 (03) : 234 - 241
  • [7] What have we learnt 50 years after the first Fontan procedure?
    Gargiulo, Gaetano D.
    Bassareo, Pier P.
    Careddu, Lucio
    Egidy-Assenza, Gabriele
    Angeli, Emanuela
    Calcaterra, Giuseppe
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2020, 21 (05) : 349 - 358
  • [8] Adult patients with Fontan circulation: What we know and how to manage adults with Fontan circulation?
    Ohuchi, Hideo
    JOURNAL OF CARDIOLOGY, 2016, 68 (3-4) : 181 - 189
  • [9] Normally and Abnormally Related Great Arteries: What Have We Learned?
    Van Praagh, Richard
    WORLD JOURNAL FOR PEDIATRIC AND CONGENITAL HEART SURGERY, 2010, 1 (03) : 364 - 385
  • [10] What have we learned from transplanting older patients?
    Varadarajan, Indumathy
    Ballen, Karen K.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (04)